Assay and Drug Development Technologies · 2007 · 346 citations · 38 references
Life SciencesBiochemistryPharmacologyBioavailabilityCancer PharmacologyInflammationBioactive Natural ProductsLipid PeroxidationMedicinal PlantsSolubility OptimizationAnti-inflammatory Natural ProductsAssayBioactive PigmentsLipid Peroxidation In Disease PathogenesisPhytochemicals In Cancer PreventionSolubilitySolubility-limited Bioavailability
Lipid peroxidation has been implicated in a variety of diseases. 4-Hydroxy-2-nonenal (HNE), a major oxidation by-product, is cytotoxic, mutagenic, and genotoxic, being involved in disease pathogenesis. Naturally occurring pharmacologically active small molecules are very attractive as natural nonsteroidal anti-inflammatory agents. Interest has greatly increased recently in the pharmacotherapeutic potential of curcumin, the yellow pigment found in the rhizomes of the perennial herb Curcuma longa (turmeric). Curcumin is efficacious against colon cancer, cystic fibrosis, and a variety of other disorders. Curcumin's full pharmacological potential is limited owing to its extremely limited water solubility. We report here that the water solubility of curcumin could be increased from 0.6 microg/ml to 7.4 microg/ml (12-fold increase) by the use of heat. Spectrophotometric (400-700 nm) and mass spectrometric profiling of the heat-extracted curcumin displays no significant heat-mediated disintegration of curcumin. Using an enzyme-linked immunosorbent assay that employed HNE modification of solid-phase antigen, we found that the heat-solubilized curcumin inhibited HNE-protein modification by 80%. Thus, inhibition of HNE modification may be a mechanism by which curcumin exerts its effect. We also report a simple assay to detect curcumin spectrophotometrically. Curcumin was solubilized in methanol and serially diluted in methanol to obtain a set of standards that were then read for optical density at 405 nm. Curcumin in the heat-solubilized samples was determined from this standard. Heat-solubilized curcumin should be considered in clinical trials involving curcumin, especially in the face of frustrating results obtained regarding curcumin-mediated correction of cystic fibrosis defects.
38
Steven M. Rowe, Stacey Miller, Eric J. Sorscher · New England Journal of Medicine · 2005 · 1.4K citations
Phase I Clinical Trial of Oral Curcumin
Ricky A. Sharma, Stephanie A. Euden, Sharon L. Platton et al. · Clinical Cancer Research · 2004 · 1.2K citations · Full text
Medicine, Oncology, Pharmacology +13
A Study on the Fate of Curcumin in the Rat
Bo Wahlström, G. Blennow · Acta Pharmacologica et Toxicologica · 1978 · 623 citations
Curcumin, a Major Constituent of Turmeric, Corrects Cystic Fibrosis Defects
Marie E. Egan, Marilyn Pearson, Scott A. Weiner et al. · Science · 2004 · 561 citations
Medicine, Cell Biology, Pharmacology +13
Curcumin induces apoptosis in human breast cancer cells through p53‐dependent Bax induction
Tathagata Choudhuri, Suman Pal, Munna L Agwarwal et al. · FEBS Letters · 2002 · 427 citations · Full text